CAMK2-related Synapthopathies Natural History Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorErasmus Medical Center

About this trial

The key endpoint for this prospective cohort study is:

Mapping of the disease course of all known patients (both children and adults, international) with a CAMK2 mutation, for which ENCORE has founded an expert clinic, and therefore has a substantial and active neuroscientific research arm combined with tertiary academic clinical care delivery for those living in the Netherlands.

Such robust clinical maps can subsequently be used for genotype-phenotype correlations and, identify clinically relevant outcome measures for prognostication, improvement of care delivery \& future clinical trials. Additionally, it will most likely generate new research questions for basic scientists who are trying to unravel the specific mechanisms of disease pathophysiology.

Eligibility criteria

Qualifiers

Subject with a (likely) pathogenic variation in one of the CAMK2 genes

Consent for anonymous registration in an (inter)national database

Disqualifiers

None

Trial design

Treatments tested in this trial

  • No intervention

Treatment groups

150 Participants
are divided into 1 treatment group

Sponsors and collaborators